MAPT and Alzheimer disease: We evaluated the proposed method using realistic PET-MRI simulations and illustrated its use in clinical examples of co-registered tau PET/dMRI data from the Alzheimer’s Disease Neuroimaging Initiative Phase 3 (ADNI3).2